HC Wainwright Issues Optimistic Outlook for OVID Earnings

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities research analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.16). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.16) EPS.

A number of other research analysts have also weighed in on OVID. Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a report on Wednesday, January 29th. Wedbush reiterated an “outperform” rating and issued a $3.00 price target (down previously from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Finally, BTIG Research decreased their price objective on shares of Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Monday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $3.03.

Ovid Therapeutics Price Performance

NASDAQ OVID opened at $0.43 on Wednesday. The company has a market cap of $30.58 million, a price-to-earnings ratio of -0.92 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. The stock’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.92. Ovid Therapeutics has a 1 year low of $0.42 and a 1 year high of $3.45.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%.

Institutional Investors Weigh In On Ovid Therapeutics

Several hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its holdings in Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after buying an additional 47,723 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Ovid Therapeutics by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock worth $1,555,000 after acquiring an additional 14,816 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Ovid Therapeutics by 4,128.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock worth $260,000 after acquiring an additional 215,189 shares in the last quarter. Barclays PLC increased its stake in shares of Ovid Therapeutics by 311.2% in the 3rd quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after purchasing an additional 63,702 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Ovid Therapeutics by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares in the last quarter. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.